Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics, Inc. (NASDAQ: DFTX ) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder.

Read the original report for the complete account of this story.